At Creative Biolabs, our scientists are working on incredibly cool things that matter. Just imagine how exciting will be if our work actually affects someone’s life. We are dedicated to using Next-IO™ programs to develop monoclonal antibody drugs or other combination therapies to treat cancer. From our standpoint, there is nothing more important than helping patients who are suffering.
We know cancers are not just a bunch of invasive and malignant cells, but also complex “organs” consisting many other recruited cells. Tumor microenvironment (TME) is constructed by the interaction between malignant cells and non-transformed cells. Our Next-IO™ programs focus on the targets in tumor microenvironment that are related to immune cells. Cells in TME contain T lymphocytes, B lymphocytes, natural killer (NK) and natural killer T (NKT) cells, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), tumor-associated neutrophils (TANs), cancer-associated fibroblasts, adipocytes, vascular endothelial cells, pericytes, and lymphatic endothelial cells etc. There are a wide range of pre-clinical and clinical approaches targeting tumor microenvironment. It is believed that TME is important in designing novel cancer therapies. Our Next-IO™ programs focus on immuno-oncology programs with potentials to bring great benefit to our partners. Please visit some sample program as follows to learn more.
Creative Biolabs is able to develop these Next-IO™ programs with our immuno-oncology expertise. Through close collaboration with distinguished scientists, our partners can spot promising candidates and acknowledge accurate pre-clinical outcomes. We are committed to providing assistance along the process of discovery to pre-clinical studies, and even IND application. If you are interested in our Next-IOTM programs, please feel free to contact us and learn more on how we can collaborate!
For lab research only, cannot be used for any clinical use.